Progress Toward Measles Elimination - Worldwide, 2000-2023.

IF 25.4 1区 医学 Q1 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH
Anna A Minta, Matt Ferrari, Sebastien Antoni, Brian Lambert, Takudzwa S Sayi, Christopher H Hsu, Claudia Steulet, Marta Gacic-Dobo, Paul A Rota, Mick N Mulders, Alice Wimmer, Anindya Sekhar Bose, Patrick O'Connor, Natasha S Crowcroft
{"title":"Progress Toward Measles Elimination - Worldwide, 2000-2023.","authors":"Anna A Minta, Matt Ferrari, Sebastien Antoni, Brian Lambert, Takudzwa S Sayi, Christopher H Hsu, Claudia Steulet, Marta Gacic-Dobo, Paul A Rota, Mick N Mulders, Alice Wimmer, Anindya Sekhar Bose, Patrick O'Connor, Natasha S Crowcroft","doi":"10.15585/mmwr.mm7345a4","DOIUrl":null,"url":null,"abstract":"<p><p>Measles vaccination effectively prevents measles, a highly contagious disease that can cause severe complications and death and requires high population immunity to interrupt transmission. This report describes measles elimination progress during 2000-2023. During 2000-2023, an estimated 60.3 million measles deaths were averted by vaccination. However, despite commitment from all six World Health Organization regions to eliminate measles, no region has successfully achieved and maintained measles elimination as of the end of 2023. During the COVID-19 pandemic, estimated global coverage with the first dose of measles-containing vaccine (MCV1) declined to 81%, the lowest level since 2008. MCV1 coverage improved to 83% in 2022 but was unchanged in 2023. From 2022 to 2023, estimated measles cases increased 20% worldwide, from 8,645,000 to 10,341,000; the number of countries experiencing large or disruptive outbreaks increased from 36 to 57. Estimated measles deaths decreased 8%, from 116,800 in 2022 to 107,500 in 2023, primarily because an increased number of cases occurred in countries with lower risk for death. The stagnation in MCV1 coverage means millions of children remain unprotected, leading to increases in cases and outbreaks. Coverage with measles-containing vaccine (MCV) is lower, and measles incidence is higher, in low-income countries and countries experiencing fragile, conflict-affected, and vulnerable settings, which exacerbate inequities. Urgent and targeted efforts are needed to ensure that all children receive 2 MCV doses and that surveillance is strengthened to hasten progress toward measles elimination.</p>","PeriodicalId":18637,"journal":{"name":"MMWR. Morbidity and mortality weekly report","volume":"73 45","pages":"1036-1042"},"PeriodicalIF":25.4000,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11576049/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"MMWR. Morbidity and mortality weekly report","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.15585/mmwr.mm7345a4","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}
引用次数: 0

Abstract

Measles vaccination effectively prevents measles, a highly contagious disease that can cause severe complications and death and requires high population immunity to interrupt transmission. This report describes measles elimination progress during 2000-2023. During 2000-2023, an estimated 60.3 million measles deaths were averted by vaccination. However, despite commitment from all six World Health Organization regions to eliminate measles, no region has successfully achieved and maintained measles elimination as of the end of 2023. During the COVID-19 pandemic, estimated global coverage with the first dose of measles-containing vaccine (MCV1) declined to 81%, the lowest level since 2008. MCV1 coverage improved to 83% in 2022 but was unchanged in 2023. From 2022 to 2023, estimated measles cases increased 20% worldwide, from 8,645,000 to 10,341,000; the number of countries experiencing large or disruptive outbreaks increased from 36 to 57. Estimated measles deaths decreased 8%, from 116,800 in 2022 to 107,500 in 2023, primarily because an increased number of cases occurred in countries with lower risk for death. The stagnation in MCV1 coverage means millions of children remain unprotected, leading to increases in cases and outbreaks. Coverage with measles-containing vaccine (MCV) is lower, and measles incidence is higher, in low-income countries and countries experiencing fragile, conflict-affected, and vulnerable settings, which exacerbate inequities. Urgent and targeted efforts are needed to ensure that all children receive 2 MCV doses and that surveillance is strengthened to hasten progress toward measles elimination.

2000-2023 年全球消除麻疹的进展情况。
麻疹疫苗接种可有效预防麻疹,麻疹是一种可导致严重并发症和死亡的高度传染性疾病,需要很高的人群免疫力才能阻断传播。本报告介绍了 2000-2023 年期间消除麻疹的进展情况。在 2000-2023 年期间,估计有 6030 万人通过接种疫苗避免了麻疹死亡。然而,尽管世界卫生组织所有六个地区都承诺消除麻疹,但截至 2023 年底,还没有一个地区成功实现并保持消除麻疹的目标。在 COVID-19 大流行期间,含麻疹成分疫苗(MCV1)第一剂的全球估计接种率降至 81%,为 2008 年以来的最低水平。2022 年,MCV1 的覆盖率提高到 83%,但在 2023 年没有变化。从 2022 年到 2023 年,全球估计麻疹病例增加了 20%,从 864.5 万例增加到 1034.1 万例;出现大规模或破坏性疫情的国家从 36 个增加到 57 个。估计麻疹死亡人数下降了 8%,从 2022 年的 116 800 人降至 2023 年的 107 500 人,主要原因是死亡风险较低的国家出现了更多病例。MCV1覆盖率停滞不前意味着数百万儿童仍未得到保护,导致病例和疫情增加。在低收入国家以及环境脆弱、受冲突影响和易受感染的国家,含麻疹成分疫苗(MCV)的覆盖率较低,麻疹发病率较高,这加剧了不平等现象。需要做出紧急和有针对性的努力,确保所有儿童接种两剂含麻疹成分疫苗,并加强监测,以加快消除麻疹的进程。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
MMWR. Morbidity and mortality weekly report
MMWR. Morbidity and mortality weekly report PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH -
CiteScore
65.40
自引率
0.90%
发文量
309
期刊介绍: The Morbidity and Mortality Weekly Report (MMWR ) series is prepared by the Centers for Disease Control and Prevention (CDC). Often called “the voice of CDC,” the MMWR series is the agency’s primary vehicle for scientific publication of timely, reliable, authoritative, accurate, objective, and useful public health information and recommendations. MMWR readership predominantly consists of physicians, nurses, public health practitioners, epidemiologists and other scientists, researchers, educators, and laboratorians.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信